|
Sign In to gain access to subscriptions and/or personal tools.
|
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis
E T Lim
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
T Berger
Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria
M Reindl
Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria
C M Dalton
MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
K Fernando
MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
G Keir
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
E J Thompson
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
D H Miller
MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
G Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK, G.Giovannoni{at}ion.ucl.ac.uk
This study investigates whether the presence of serum and plasma anti-myelin oligodendrocyte glycoprotein (MOG) and anti-myelin basic protein (MBP) in patients presenting with a clinically isolated syndrome compatible with demyelination (CIS) predicts early conversion to multiple sclerosis (MS). Forty-seven patients with CIS (46 with optic neuritis) had anti-MOG and anti-MBP antibodies analysed at baseline, and clinical and magnetic resonance imaging assessments. There was no evidence that the MS status based on either the McDonald or Poser criteria relates to the antibody status.
Key Words: anti-myelin antibodies clinically isolated syndrome multiple sclerosis
Multiple Sclerosis, Vol. 11, No. 4,
492-494 (2005)
DOI: 10.1191/1352458505ms1187sr

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M H J Vogt, C E Teunissen, E Iacobaeus, D A M Heijnen, E C W Breij, T Olsson, L Brundin, J Killestein, and C. D Dijkstra
Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
October 1, 2009;
80(10):
1110 - 1115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, K. L. Munger, M. Reindl, E. J. O'Reilly, L. I. Levin, T. Berger, and A. Ascherio
Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults
Neurology,
October 7, 2008;
71(15):
1142 - 1146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Breithaupt, B. Schafer, H. Pellkofer, R. Huber, C. Linington, and U. Jacob
Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific Autoantibody Response Is Focused on One Dominant Conformational Epitope Region in Rodents
J. Immunol.,
July 15, 2008;
181(2):
1255 - 1263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Amor and G. Giovannoni
Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis are we there yet?
Multiple Sclerosis,
November 1, 2007;
13(9):
1083 - 1085.
[PDF]
|
 |
|

|
 |

|
 |
 
V. Tomassini, L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, and C. Pozzilli
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
Multiple Sclerosis,
November 1, 2007;
13(9):
1086 - 1094.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kuhle, C. Pohl, M. Mehling, G. Edan, M. S. Freedman, H.-P. Hartung, C. H. Polman, D. H. Miller, X. Montalban, F. Barkhof, et al.
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
N. Engl. J. Med.,
January 25, 2007;
356(4):
371 - 378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Pelayo, M. Tintore, X. Montalban, A. Rovira, C. Espejo, M. Reindl, and T. Berger
Antimyelin Antibodies with No Progression to Multiple Sclerosis
N. Engl. J. Med.,
January 25, 2007;
356(4):
426 - 428.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S J Pittock, M Reindl, S Achenbach, T Berger, W Bruck, F Konig, Y Morales, H Lassmann, S Bryant, S B Moore, et al.
Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
Multiple Sclerosis,
January 1, 2007;
13(1):
7 - 16.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C H Polman and J Killestein
Anti-myelin antibodies in multiple sclerosis: clinically useful?
J. Neurol. Neurosurg. Psychiatry,
June 1, 2006;
77(6):
712 - 712.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Rauer, B Euler, M Reindl, and T Berger
Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
J. Neurol. Neurosurg. Psychiatry,
June 1, 2006;
77(6):
739 - 742.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|